FDA Approved: BALVERSA — Original Application (Janssen Products LP)

View source ↗

Summary

The FDA documents the original approval of BALVERSA (erdafitinib) by Janssen Products LP for urothelial carcinoma with FGFR genetic alterations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

ORIG AP for BALVERSA (ERDAFITINIB)